[123I-metaiodobenzylguanidine (MIBG) scintigraphy for the staging of neuroblastoma]

Kaku Igaku. 1998 Nov;35(9):835-42.
[Article in Japanese]

Abstract

Nineteen children with neuroblastoma (aged 2 w.-7 y.o.) were studied to evaluate the optimal scan conditions for Iodine-123-Metaiodobenzylguanidine (MIBG) scintigraphy for accurate staging at the time of diagnosis. Six and 24 hours after an injection of 123I-MIBG, whole body image and truncal spot and SPECT images were obtained. Compared with other studies (CT or MRI and bone scintigraphy), each 123I-MIBG image was evaluated visually to investigate which image can demonstrate the extent of neuroblastoma most exactly. MIBG images demonstrated primary tumors in all patients, and metastatic lymphadenopathy in 8 of 9 patients. Twenty-four hour SPECT images gave us the most detailed information about the extent of abnormal accumulation. As to bone and bone marrow lesions, 6 hour images were superior to 24 hour images in detectability. Moreover, MIBG showed many more lesions and more extended accumulation than the bone scan. 123I-MIBG scintigraphy was very useful in detecting neuroblastomas. In order to get the most valuable information, both delayed SPECT and early whole body planar images should be obtained.

Publication types

  • Clinical Trial

MeSH terms

  • 3-Iodobenzylguanidine*
  • Adrenal Gland Neoplasms / diagnostic imaging*
  • Adrenal Gland Neoplasms / pathology
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / secondary
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Iodine Radioisotopes
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / secondary
  • Lymphatic Metastasis
  • Male
  • Neoplasm Staging
  • Neuroblastoma / diagnostic imaging*
  • Neuroblastoma / secondary
  • Radiopharmaceuticals*
  • Time Factors
  • Tomography, Emission-Computed, Single-Photon

Substances

  • Iodine Radioisotopes
  • Radiopharmaceuticals
  • 3-Iodobenzylguanidine